Company Registration No. SC579331 (Scotland)
Cytochroma Limited
Unaudited accounts
for the year ended 31 October 2025
Cytochroma Limited
Unaudited accounts
Contents
Cytochroma Limited
Company Information
for the year ended 31 October 2025
Directors
Dr Richard Eglen
Dr Katherine Rachel Cameron
Company Number
SC579331 (Scotland)
Registered Office
Roslin Innovation Centre
Easter Bush
Edinburgh
EH25 9RG
United Kingdom
Accountants
FinFlare Limited
Mitchell House
5 Mitchell Street
Edinburgh
Midlothian
EH6 7BD
Cytochroma Limited
Statement of financial position
as at 31 October 2025
Tangible assets
4,591
9,464
Cash at bank and in hand
290,057
30,516
Creditors: amounts falling due within one year
(84,928)
(76,692)
Net current assets/(liabilities)
250,983
(13,186)
Total assets less current liabilities
255,574
(3,722)
Creditors: amounts falling due after more than one year
(274,910)
(38,951)
Net liabilities
(19,336)
(42,673)
Called up share capital
1
1
Share premium
541,373
541,373
Profit and loss account
(560,710)
(584,047)
Shareholders' funds
(19,336)
(42,673)
For the year ending 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 13 May 2026 and were signed on its behalf by
Dr Katherine Rachel Cameron
Director
Company Registration No. SC579331
Cytochroma Limited
Notes to the Accounts
for the year ended 31 October 2025
Cytochroma Limited is a private company, limited by shares, registered in Scotland, registration number SC579331. The registered office is Roslin Innovation Centre, Easter Bush, Edinburgh, EH25 9RG, United Kingdom.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
The accounts are presented in £ sterling.
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Turnover from the sale of goods is recognised when goods have been delivered to customers such that risks and rewards of ownership have transferred to them. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Plant & machinery
Straight line over 5 years
Fixtures & fittings
Straight line over 3 years
Computer equipment
Straight line over 3 years
Expenditure on research and development is written off in the year in which it is incurred.
Government grants in relation to tangible fixed assets are credited to profit and loss account over the useful lives of the related assets, whereas those in relation to expenditure are credited when the expenditure is charged to profit and loss.
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rates of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
The company operates a defined contribution scheme for the benefit of its employees. Contributions payable are recognised in the profit and loss account when due.
Cytochroma Limited
Notes to the Accounts
for the year ended 31 October 2025
Basic financial instruments are recognised at amortised cost, except for investments in non-convertible preference and non-puttable ordinary shares which are measured at fair value, with changes recognised in profit or loss. Derivative financial instruments are initially recorded at cost and thereafter at fair value with changes recognised in profit or loss.
In preparing these financial statements, the directors have assessed whether there are any material
uncertainties related to events or conditions that cast significant doubt upon the company’s ability to
continue as a going concern. In making this assessment, the directors take into account all available
information about the future which is at least 12 months from the date that the financial statements are
authorised for issue.
The directors consider that the company has adequate resources to continue in business for the
foreseeable future and that it is appropriate to adopt the going concern basis in preparing the financial
statements.
4
Tangible fixed assets
Plant & machinery
Fixtures & fittings
Computer equipment
Total
Cost or valuation
At cost
At cost
At cost
At 1 November 2024
84,294
-
8,725
93,019
Additions
-
500
1,905
2,405
At 31 October 2025
84,294
500
10,630
95,424
At 1 November 2024
76,020
-
7,535
83,555
Charge for the year
6,315
69
894
7,278
At 31 October 2025
82,335
69
8,429
90,833
At 31 October 2025
1,959
431
2,201
4,591
At 31 October 2024
8,274
-
1,190
9,464
Amounts falling due within one year
Accrued income and prepayments
1,683
-
Other debtors
43,685
15,853
Cytochroma Limited
Notes to the Accounts
for the year ended 31 October 2025
6
Creditors: amounts falling due within one year
2025
2024
Bank loans and overdrafts
32,073
26,298
Trade creditors
43,311
16,166
Taxes and social security
5,937
2,637
Loans from directors
(213)
-
7
Creditors: amounts falling due after more than one year
2025
2024
8
Average number of employees
During the year the average number of employees was 3 (2024: 3).